Innovative Therapies for Children with Cancer
A Study of Oral LOXO-292 in Pediatric Patients With Advanced Solid or Primary Central Nervous System Tumors
An Open-Label, Single-Arm, Phase 1/2 Study Evaluating the Safety and Efficacy of Single- Agent Ponatinib for the Treatment of advanced Leukemias or Solid Tumors in Pediatric Participants
PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION AND EXPANSION STUDY OF ENTRECTINIB (RXDX-101) IN CHILDREN AND ADOLESCENTS WITH NO CURATIVE FIRST-LINE TREATMENT OPTION, RECURRENT OR REFRACTORY SOLID TUMORS AND PRIMARY CNS TUMORS
A Phase 1b, Dose Escalation Study of Abemaciclib in Combination with Temozolomide and Irinotecan (triplet escalation) and Abemaciclib in combination with Temozolomidea
A Randomized, Open-Label Phase 1/2 Study Evaluating Ramucirumab in Pediatric Patients and Young Adults with Relapsed, Recurrent, or Refractory Synovial Sarcoma
Pilot study of nivolumab in paediatric patients with hypermutant cancers
A randomised phase IIb trial of BEvACizumab added to Temozolomide ± IrinOtecan for children with refractory/relapsed Neuroblastoma
A phase IB study of crizotinib (Xalcori®) in pediatric malignancies with anaplastic lymphoma kinase (ALK) aberrations
